Trending:
News
-
25 April 2018
World Malaria Day: WHO spotlights global health campaign
World Malaria Day, an annual event that recognises global efforts to control malaria, takes place on 25 April. This year, the World Health Organisation (WHO), along with partner organisations, is...
-
25 April 2018
Tweaking diabetes treatments can improve effectiveness
Research carried out by Imperial College London has showed that small alterations to existing diabetes treatments can increase their effectiveness by changing their interactions with cells.
-
25 April 2018
Topas partners with Boehringer for vector-based drugs
German biotechnology company Topas Therapeutics has partnered with Boehringer Ingelheim to focus on antigen-specific tolerance induction to tackle anti-drug antibodies (ADA).
-
25 April 2018
Fish protein may reduce Parkinson’s disease risk
Researchers from Chalmers University of Technology in Sweden have discovered that eating fish can prevent formation of some protein structures associated with Parkinson’s disease.
-
24 April 2018
Takeda makes fourth offer of £44.3bn for Shire takeover
Takeda Pharmaceutical Company has put forward a fourth offer to acquire Shire, a day after the Irish biopharmaceutical company best known for ADHD drug Adderall rejected a previous offer.
-
24 April 2018
Biogen and Ionis to develop neurological drugs in $1bn deal
Biogen has formed a strategic alliance worth $1bn with Ionis Pharmaceuticals to develop a pipeline of drug candidates for multiple neurological diseases.
-
24 April 2018
Pfizer’s Trumenba gets breakthrough status for meningococcal disease
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Pfizer’s Trumenba for meningococcal B disease in children aged between one and nine.
-
24 April 2018
Belgium’s UCB buys Proximagen’s epilepsy drug
Belgian biopharmaceutical company UCB has acquired an anti-epilepsy medication, Midazolam nasal spray (USL261), from Proximagen for $150m.
-
23 April 2018
Fresenius backs out of Akorn buyout over data integrity requirements
Fresenius has announced that it is terminating a merger agreement with generic pharmaceutical company Akorn due to Akorn’s ‘failure to fulfil several closing conditions’.
-
23 April 2018
DEA proposes rules to curb the manufacture of opioids
The US Drug Enforcement Agency (DEA) has proposed stricter rules for the manufacture of prescription opioids by drug makers.
